Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy

Phase 3

Terminated

Conditions: Recurrent Rectal Cancer
Stage IVB Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Rectal Cancer
Recurrent Colon Cancer
Stage IVA Colon Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: fluorouracil
Biological: cetuximab
Biological: bevacizumab

First Posted Date: 2007-07-11

Last Posted Date: 2014-07-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 72

Registration Number: NCT00499369

Locations: 🇺🇸
Graham Hospital Association, Canton, Illinois, United States
🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States

and more 378 locations

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer
Metastatic Cancer

Interventions: Drug: dexamethasone
Drug: floxuridine
Drug: irinotecan hydrochloride
Drug: fluorouracil
Drug: oxaliplatin
Drug: leucovorin calcium

First Posted Date: 2007-06-27

Last Posted Date: 2024-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT00492999

Locations: 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States

and more 1 locations

Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer

Phase 3

Conditions: Colorectal Cancer
Metastatic Cancer

Interventions: Biological: cetuximab
Drug: capecitabine
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Other: study of socioeconomic and demographic variables
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: quality-of-life assessment

First Posted Date: 2007-06-05

Last Posted Date: 2013-01-23

Lead Sponsor: University of Southampton

Target Recruit Count: 340

Registration Number: NCT00482222

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧
St. Mary's Hospital, Newport, England, United Kingdom
🇬🇧
Royal Marsden - London, London, England, United Kingdom

and more 19 locations

Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery

Phase 2

Conditions: Liver Cancer

First Posted Date: 2007-05-10

Last Posted Date: 2011-06-22

Lead Sponsor: National Cancer Centre, Singapore

Target Recruit Count: 54

Registration Number: NCT00471484

Locations: 🇸🇬
National Cancer Centre - Singapore, Singapore, Singapore

Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Irinotecan
Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Bevacizumab

First Posted Date: 2007-05-04

Last Posted Date: 2010-08-19

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 330

Registration Number: NCT00469443

Locations: 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece

and more 5 locations

Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Cetuximab
Drug: 5-FU
Drug: Cisplatin
Radiation: Accelerated fraction radiotherapy with concomitant boost
Drug: Hydroxyurea
Radiation: Twice-daily radiation

First Posted Date: 2007-05-02

Last Posted Date: 2019-10-09

Lead Sponsor: University of Chicago

Target Recruit Count: 110

Registration Number: NCT00468169

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Genetic: polymorphism analysis

First Posted Date: 2007-04-27

Last Posted Date: 2022-11-01

Lead Sponsor: Institut Bergonié

Target Recruit Count: 62

Registration Number: NCT00467142

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France

Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Cancer of the Larynx
Nose Neoplasms
Paranasal Sinus Neoplasms
Cancer of the Oral Cavity
Head and Neck Cancer
Cancer of the Pharynx

Interventions: Drug: Cetuximab
Drug: Hydroxyurea
Drug: Fluorouracil
Procedure: radiotherapy

First Posted Date: 2007-04-19

Last Posted Date: 2018-03-13

Lead Sponsor: Johnny Kao

Target Recruit Count: 33

Registration Number: NCT00462735

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2007-04-19

Last Posted Date: 2016-01-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 35

Registration Number: NCT00462501

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Arsenic trioxide
Drug: Fluorouracil
Drug: Leucovorin calcium
Other: Plasma levels of elemental arsenic
Genetic: Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis
Procedure: Tumor Biopsy (Fine-Needle Aspiration)

First Posted Date: 2007-03-19

Last Posted Date: 2016-12-15

Lead Sponsor: University of Miami

Target Recruit Count: 13

Registration Number: NCT00449137

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy